排序方式: 共有78条查询结果,搜索用时 15 毫秒
41.
Geraldine AC Lim Erica G Jewell Xi Li Timothy A Erwin Christopher Love Jacqueline Batley German Spangenberg David Edwards 《BMC plant biology》2007,7(1):40
Background
Molecular genetic maps provide a means to link heritable traits with underlying genome sequence variation. Several genetic maps have been constructed for Brassica species, yet to date, there has been no simple means to compare this information or to associate mapped traits with the genome sequence of the related model plant, Arabidopsis. 相似文献42.
Irene EM Bultink D?rte Hamann Marc A Seelen Margreet H Hart Ben AC Dijkmans Mohamed R Daha Alexandre E Voskuyl 《Arthritis research & therapy》2007,8(6):R183
Infection imposes a serious burden on patients with systemic lupus erythematosus (SLE). The increased infection rate in SLE
patients has been attributed in part to defects of immune defence. Recently, the lectin pathway of complement activation has
also been suggested to play a role in the occurrence of infections in SLE. In previous studies, SLE patients homozygous for
mannose-binding lectin (MBL) variant alleles were at an increased risk of acquiring serious infections in comparison with
patients who were heterozygous or homozygous for the normal allele. This association suggests a correlation between functional
MBL level and occurrence of infections in SLE patients. We therefore investigated the biological activity of MBL and its relationship
with the occurrence of infections in patients with SLE. Demographic and clinical data were collected in 103 patients with
SLE. Functional MBL serum levels and MBL-induced C4 deposition were measured by enzyme-linked immunosorbent assay using mannan
as coat and an MBL- or C4b-specific monoclonal antibody. The complete MBL-dependent pathway activity was determined by using
an assay that measures the complete MBL pathway activity in serum, starting with binding of MBL to mannan, and was detected
with a specific monoclonal antibody against C5b-9. Charts were systematically reviewed to obtain information on documented
infections since diagnosis of SLE. Major infections were defined as infections requiring hospital admission and intravenous
administration of antibiotics. In total, 115 infections since diagnosis of lupus, including 42 major infections, were documented
in the 103 SLE patients (mean age 41 ± 13 years, mean disease duration 7 ± 4 years). The percentage of SLE patients with severe
MBL deficiency was similar to that in 100 healthy controls: 13% versus 14%, respectively. Although deposition of C4 to mannan
and MBL pathway activity were reduced in 21% and 43% of 103 SLE patients, respectively, neither functional MBL serum levels
nor MBL pathway activity was associated with infections or major infections in regression analyses. In conclusion, SLE patients
frequently suffer from infections, but deficiency of functional MBL does not confer additional risk. 相似文献
43.
Timm Konold A Robin Sayers Amanda Sach Gemma E Bone Steven van Winden Gerald AH Wells Marion M Simmons Michael J Stack Angus Wear Steve AC Hawkins 《BMC veterinary research》2010,6(1):53
Background
Various clinical protocols have been developed to aid in the clinical diagnosis of classical bovine spongiform encephalopathy (BSE), which is confirmed by postmortem examinations based on vacuolation and accumulation of disease-associated prion protein (PrPd) in the brain. The present study investigated the occurrence and progression of sixty selected clinical signs and behaviour combinations in 513 experimentally exposed cattle subsequently categorised postmortem as confirmed or unconfirmed BSE cases. Appropriate undosed or saline inoculated controls were examined similarly and the data analysed to explore the possible occurrence of BSE-specific clinical expression in animals unconfirmed by postmortem examinations. 相似文献44.
Overbeek MJ Boonstra A Voskuyl AE Vonk MC Vonk-Noordegraaf A van Berkel MP Mooi WJ Dijkmans BA Hondema LS Smit EF Grünberg K 《Arthritis research & therapy》2011,13(2):R61-13
Introduction
Systemic sclerosis (SSc) complicated by pulmonary arterial hypertension (PAH) carries a poor prognosis, despite pulmonary vascular dilating therapy. Platelet-derived growth factor receptor-β (PDGFR-β) and epidermal growth factor receptor (EGFR) are potential therapeutic targets for PAH because of their proliferative effects on vessel remodelling. To explore their role in SScPAH, we compared PDGFR- and EGFR-mmunoreactivity in lung tissue specimens from SScPAH. We compared staining patterns with idiopathic PAH (IPAH) and pulmonary veno-occlusive disease (PVOD), as SScPAH vasculopathy differs from IPAH and sometimes displays features of PVOD. Immunoreactivity patterns of phosphorylated PDGFR-β (pPDGFR-β) and the ligand PDGF-B were evaluated to provide more insight into the patterns of PDGFR-b activation.Methods
Lung tissue specimens from five SScPAH, nine IPAH, six PVOD patients and five controls were examined. Immunoreactivity was scored for presence, distribution and intensity.Results
All SScPAH and three of nine IPAH cases (P = 0.03) showed PDGFR-β-immunoreactivity in small vessels (arterioles/venules); of five SScPAH vs. two of nine IPAH cases (P = 0.02) showed venous immunoreactivity. In small vessels, intensity was stronger in SScPAH vs. IPAH. No differences were found between SScPAH and PVOD. One of five normal controls demonstrated focally mild immunoreactivity. There were no differences in PDGF-ligand and pPDGFR-b-immunoreactivity between patient groups; however, pPDGFR-b-immunoreactivity tended to be more prevalent in SScPAH small vasculature compared to IPAH. Vascular EGFR-immunoreactivity was limited to arterial and arteriolar walls, without differences between groups. No immunoreactivity was observed in vasculature of normals.Conclusions
PDGFR-β-immunoreactivity in SScPAH is more common and intense in small- and post-capillary vessels than in IPAH and does not differ from PVOD, fitting in with histomorphological distribution of vasculopathy. PDGFR-β immunoreactivity pattern is not paralleled by pPDGFR-β or PDGF-B patterns. PDGFR-β- and EGFR-immunoreactivity of pulmonary vessels distinguishes PAH patients from controls. 相似文献45.
Geraint B Rogers Leah Cuthbertson Lucas R Hoffman Peter AC Wing Christopher Pope Danny A P Hooftman Andrew K Lilley Anna Oliver Mary P Carroll Kenneth D Bruce Christopher J van der Gast 《The ISME journal》2013,7(4):697-706
High-throughput pyrosequencing and quantitative PCR (Q-PCR) analysis offer greatly improved accuracy and depth of characterisation of lower respiratory infections. However, such approaches suffer from an inability to distinguish between DNA derived from viable and non-viable bacteria. This discrimination represents an important step in characterising microbial communities, particularly in contexts with poor clearance of material or high antimicrobial stress, as non-viable bacteria and extracellular DNA can contribute significantly to analyses. Pre-treatment of samples with propidium monoazide (PMA) is an effective approach to non-viable cell exclusion (NVCE). However, the impact of NVCE on microbial community characteristics (abundance, diversity, composition and structure) is not known. Here, adult cystic fibrosis (CF) sputum samples were used as a paradigm. The effects of PMA treatment on CF sputum bacterial community characteristics, as analysed by pyrosequencing and enumeration by species-specific (Pseudomonas aeruginosa) and total bacterial Q-PCR, were assessed. At the local community level, abundances of both total bacteria and of P. aeruginosa were significantly lower in PMA-treated sample portions. Meta-analysis indicated no overall significant differences in diversity; however, PMA treatment resulted in a significant alteration in local community membership in all cases. In contrast, at the metacommunity level, PMA treatment resulted in an increase in community evenness, driven by an increase in diversity, predominately representing rare community members. Importantly, PMA treatment facilitated the detection of both recognised and emerging CF pathogens, significantly influencing ‘core'' and ‘satellite'' taxa group membership. Our findings suggest failure to implement NVCE may result in skewed bacterial community analyses. 相似文献
46.
Christophe Rodriguez Cathia Soulié Anne-Geneviève Marcelin Vincent Calvez Diane Descamps Charlotte Charpentier Philippe Flandre Patricia Recordon-Pinson Pantxika Bellecave Jean-Michel Pawlotsky Bernard Masquelier the ANRS AC Study Group 《PloS one》2015,10(6)
Background
Maraviroc is an HIV entry inhibitor that alters the conformation of CCR5 and is poorly efficient in patients infected by viruses that use CXCR4 as an entry coreceptor. The goal of this study was to assess the capacity of ultra-deep pyrosequencing (UDPS) and different data analysis approaches to characterize HIV tropism at baseline and predict the therapeutic outcome on maraviroc treatment.Methods
113 patients with detectable HIV-1 RNA on HAART were treated with maraviroc. The virological response was assessed at months 1, 3 and 6. The sequence of the HIV V3 loop was determined at baseline and prediction of maraviroc response by different software and interpretation algorithms was analyzed.Results
UDPS followed by analysis with the Pyrotrop software or geno2pheno algorithm provided better prediction of the response to maraviroc than Sanger sequencing. We also found that the H34Y/S substitution in the V3 loop was the strongest individual predictor of maraviroc response, stronger than substitutions at positions 11 or 25 classically used in interpretation algorithms.Conclusions
UDPS is a powerful tool that can be used with confidence to predict maraviroc response in HIV-1-infected patients. Improvement of the predictive value of interpretation algorithms is possible and our results suggest that adding the H34S/Y substitution would substantially improve the performance of the 11/25/charge rule. 相似文献47.
Denusa M Veríssimo Renata FC Leit?o S?nia D Figueiró Júlio C Góes Vilma Lima Charles O Silveira Gerly AC Brito 《Experimental biology and medicine (Maywood, N.J.)》2015,240(2):175-184
The aim of this study was to evaluate the bone regenerative effect of glutaraldehyde (GA) cross-linking on mineralized polyanionic collagen membranes in critical-sized defects on rat calvarias. Bone calvarial defects were induced in Wistar rats, which were then divided into five groups: a sham group; a control group, which received a commercial membrane; and GA, 25GA, and 75GA groups, which received one of three different polyanionic collagen membranes mineralized by 0, 25, or 75 hydroxyapatite cycles and then cross-linked by GA. Bone formation was evaluated based on digital radiography and computerized tomography. Histological analyses were performed 4 and 12 weeks after the surgical procedure to observe bone formation, membrane resorption, and fibrous tissue surrounding the membranes. Measurement of myeloperoxidase activity, tumor necrosis factor alpha, and interleukin 1beta production was performed 24 h after surgery. The percentage of new bone formation in the GA, 25GA, and 75GA groups was higher compared with the control and sham groups. In the GA and 25 GA groups, the membranes were still in place and were contained in a thick fibrous capsule after 12 weeks. No significant difference was found among the groups regarding myeloperoxidase activity and interleukin 1beta levels, although the GA, 25GA, and 75GA groups presented decreased levels of tumor necrosis factor alpha compared with the control group. These new GA cross-linked membranes accelerated bone healing of the calvarium defects and did not induce inflammation. In addition, unlike the control membrane, the experimental membranes were not absorbed during the analyzed period, so they may offer advantages in large bone defects where prolonged membrane barrier functions are desirable. 相似文献
48.
Jennie Ursum Wouter H Bos Rob J van de Stadt Ben AC Dijkmans Dirkjan van Schaardenburg 《Arthritis research & therapy》2009,11(3):R75-6
Introduction
The aim of this study was to examine seroconversion and the relationship with age and inflammation of autoantibodies in a large group of patients attending an outpatient rheumatology clinic. 相似文献49.
Hennie G Raterman Alexandre E Voskuyl Ben AC Dijkmans Michael T Nurmohamed 《Arthritis research & therapy》2009,11(5):413-2
With great interest, we read the article by Toms and colleagues [1] in the previous issue of Arthritis Research & Therapy, in which they assessed prevalences of metabolic syndrome (MetS) in rheumatoid arthritis (RA) patients. Moreover, they identified demographic and clinical factors that may be associated with MetS. Toms and colleagues found prevalences of up to 45% of MetS and demonstrated older age and health status (health assessment questionnaire) to be associated with MetS irrespectively of the definition used. Of most interest, an association between methotrexate (MTX) use and decreased presence of MetS was observed in patients more than 60 years of age. The investigators hypothesized that this may be attributed to a drug-specific effect (and not to an anti-inflammatory effect) either by changing levels of adenosine, which is known to interact with glucose and lipid metabolism, or by an indirect effect mediated through concomitant folic acid administration, thereby decreasing homocysteine levels.Recently, we also examined the prevalence of MetS in (a subgroup of) RA patients in the CARRÉ investigation, a prospective cohort study on prevalent and incident cardiovascular disease and its underlying cardiovascular risk factors [2]. The findings of Toms and colleagues stimulated us to perform additional analyses in our total study population (n = 353).The prevalences of MetS were 35% and 25% (Table (Table1)1) according to criteria of National Cholesterol Education Program (NCEP) 2004 and NCEP 2001, respectively. In multivariate backward regression analyses, we found significant associations between body mass index, pulse rate, creatinine levels, hypothyroidism and diabetes mellitus and the presence of MetS independently of the criteria used (Table (Table2).2). However, an independent association between single use of MTX or use of MTX in combination with other disease-modifying antirheumatic drugs, on the one hand, and a decreased prevalence of MetS, on the other hand, could not be demonstrated (even in the subgroup of patients over the age of 60).
Open in a separate windowaMetabolic syndrome (MetS) according to National Cholesterol Education Program (NCEP) 2001; bMetS according to NCEP 2004. Continuous variables are presented as means (± standard deviations) in cases of normal distribution or as medians (interquartile ranges) in cases of non-normal distribution. BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; MTX, methotrexate; RA, rheumatoid arthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor.
Open in a separate windowaIn multivariate analyses, the following variables were used: gender, age, prednisolone only, methotrexate only, sulfasalazine only, hydroxychloroquine only, tumour necrosis factor-blocking agents, combination of disease-modifying antirheumatic drugs, pack-years, smoking, erosions, DAS28 (disease activity score using 28 joint counts), body mass index, pulse rate, creatinine levels, renal clearance, hypothyroidism and diabetes mellitus. CI, confidence interval; OR, odds ratio.Therefore, to get more support for a drug-specific effect, it is of interest to know whether or not in the study of Toms and colleagues the MTX effect was present only in the group of RA patients with single use of MTX or in the group of MTX-treated patients with other antirheumatic drugs. As patients with MetS were significantly older, it would give further information whether age was an independent risk factor for MetS in regression analyses. Moreover, as readers, we are not informed about comorbidities like diabetes and clinical hypothyroidism, which are notorious cardiometabolic risk factors. On the whole, we could not confirm a plausible protective role for the use of MTX and presence of MetS, and hence further investigation is required to explain the discrepancy between our findings and those of Toms and colleagues. 相似文献
Table 1
Characteristics of the study populationMetS presenta | MetS absenta | MetS presentb | MetS absentb | |||
---|---|---|---|---|---|---|
n = 84 | n = 265 | n = 121 | n = 228 | P valuea | P valueb | |
Demographics | ||||||
Age, years | 63.8 (± 8) | 63.1 (± 7) | 64.3 (± 8) | 62.7 (± 7) | 0.46 | 0.045 |
Female, percentage | 76 | 63 | 74 | 62 | 0.022 | 0.028 |
RA-related characteristics | ||||||
DAS28 | 4.2 (± 1.3) | 3.9 (± 1.4) | 4.1 (± 1.3) | 3.8 (± 1.4) | 0.21 | 0.062 |
ESR, mm/hour | 22 (10-35) | 16 (9-30) | 20 (10-34) | 17 (9-31) | 0.059 | 0.33 |
CRP, mg/L | 11 (4-21) | 6 (3-16) | 8 (3-18) | 6 (3-19) | 0.021 | 0.46 |
RA duration, years | 7 (4-10) | 7 (4-10) | 7 (4-10) | 7 (5-10) | 0.83 | 0.19 |
Erosion, percentage | 77 | 83 | 79 | 83 | 0.20 | 0.36 |
Number of DMARDs | 1 (1-2) | 1 (1-1) | 1 (1-2) | 1 (1-1) | 0.26 | 0.43 |
MTX current, percentage | 62 | 60 | 63 | 59 | 0.71 | 0.46 |
MTX only, percentage | 39 | 39 | 41 | 38 | 0.95 | 0.67 |
SSZ only, percentage | 8 | 13 | 9 | 14 | 0.23 | 0.22 |
HCQ only, percentage | 1 | 4 | 3 | 4 | 0.31 | 0.55 |
Combination of DMARDs, percentage | 31 | 25 | 29 | 25 | 0.24 | 0.38 |
TNF-blocking agent, percentage | 11 | 9 | 11 | 9 | 0.73 | 0.65 |
Prednisolone only, percentage | 1 | 2 | 3 | 1 | 1.00 | 0.42 |
Cardiovascular risk factors | ||||||
Current smoker, percentage | 26 | 31 | 25 | 32 | 0.42 | 0.15 |
Pack-years, years | 17 (0-34) | 19 (2-38) | 19 (0-35) | 18 (2-38) | 0.23 | 0.75 |
BMI, kg/m2 | 30 (± 4) | 26 (± 5) | 29 (± 4) | 25 (± 5) | < 0.001 | < 0.001 |
Creatinine, μmol/L | 89 (± 21) | 89 (± 16) | 91 (± 22) | 87 (± 14) | 0.99 | 0.070 |
Renal clearance, mL/minute | 81 (± 24) | 72 (± 19) | 77 (± 23) | 73 (± 19) | 0.003 | 0.062 |
Pulse, beats per minute | 76 (± 11) | 73 (± 9) | 75 (± 11) | 73 (± 9) | 0.005 | 0.015 |
Diabetes mellitus, percentage | 14 | 3 | 12 | 3 | < 0.001 | 0.001 |
Hypothyroidism, percentage | 12 | 2 | 9 | 2 | 0.001 | 0.003 |
Table 2
Variables associated with metabolic syndromeUnivariate | Multivariatea | |||||
---|---|---|---|---|---|---|
OR | 95% CI | P value | OR | 95% CI | P value | |
Body mass index | 1.2 | 1.1-1.3 | < 0.001 | 1.2 | 1.1-1.3 | < 0.001 |
Pulse | 1.03 | 1.01-1.06 | 0.011 | 1.03 | 1.00-1.06 | 0.020 |
Creatinine | 1.01 | 1.00-1.02 | 0.080 | 1.02 | 1.00-1.03 | 0.017 |
Hypothyroidism | 4.5 | 1.5-13.2 | 0.007 | 4.7 | 1.5-15.0 | 0.009 |
Diabetes mellitus | 4.8 | 1.8-12.9 | 0.002 | 4.5 | 1.4-15.2 | 0.014 |
50.
Victor X Jin Gregory AC Singer Francisco J Agosto-Pérez Sandya Liyanarachchi Ramana V Davuluri 《BMC bioinformatics》2006,7(1):114-13